BALLY'S CORP (BALY)

US05875B1061 - Common Stock

13  -0.16 (-1.22%)

After market: 13 0 (0%)

Fundamental Rating

2

Taking everything into account, BALY scores 2 out of 10 in our fundamental rating. BALY was compared to 135 industry peers in the Hotels, Restaurants & Leisure industry. BALY has a bad profitability rating. Also its financial health evaluation is rather negative. BALY is quite expensive at the moment. It does show a decent growth rate.



2

1. Profitability

1.1 Basic Checks

BALY had negative earnings in the past year.
In the past year BALY had a positive cash flow from operations.
BALY had negative earnings in 4 of the past 5 years.
BALY had a positive operating cash flow in each of the past 5 years.

1.2 Ratios

BALY has a worse Return On Assets (-2.73%) than 73.88% of its industry peers.
Looking at the Return On Equity, with a value of -29.52%, BALY is doing worse than 64.18% of the companies in the same industry.
BALY has a worse Return On Invested Capital (1.38%) than 73.13% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for BALY is significantly below the industry average of 10.07%.
Industry RankSector Rank
ROA -2.73%
ROE -29.52%
ROIC 1.38%
ROA(3y)-3.75%
ROA(5y)-1.23%
ROE(3y)-29.81%
ROE(5y)-13.01%
ROIC(3y)2.08%
ROIC(5y)3.54%

1.3 Margins

BALY has a worse Operating Margin (4.27%) than 65.67% of its industry peers.
In the last couple of years the Operating Margin of BALY has declined.
BALY has a better Gross Margin (54.87%) than 62.69% of its industry peers.
BALY's Gross Margin has declined in the last couple of years.
Industry RankSector Rank
OM 4.27%
PM (TTM) N/A
GM 54.87%
OM growth 3Y-4.68%
OM growth 5Y-32.89%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.4%
GM growth 5Y-4.87%

1

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), BALY is destroying value.
BALY has less shares outstanding than it did 1 year ago.
Compared to 5 years ago, BALY has more shares outstanding
BALY has a better debt/assets ratio than last year.

2.2 Solvency

Based on the Altman-Z score of 0.29, we must say that BALY is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of 0.29, BALY is doing worse than 78.36% of the companies in the same industry.
BALY has a Debt/Equity ratio of 5.73. This is a high value indicating a heavy dependency on external financing.
The Debt to Equity ratio of BALY (5.73) is worse than 64.18% of its industry peers.
Industry RankSector Rank
Debt/Equity 5.73
Debt/FCF N/A
Altman-Z 0.29
ROIC/WACC0.2
WACC6.89%

2.3 Liquidity

A Current Ratio of 0.65 indicates that BALY may have some problems paying its short term obligations.
BALY has a Current ratio of 0.65. This is in the lower half of the industry: BALY underperforms 69.40% of its industry peers.
BALY has a Quick Ratio of 0.65. This is a bad value and indicates that BALY is not financially healthy enough and could expect problems in meeting its short term obligations.
BALY has a Quick ratio of 0.64. This is in the lower half of the industry: BALY underperforms 68.66% of its industry peers.
Industry RankSector Rank
Current Ratio 0.65
Quick Ratio 0.64

4

3. Growth

3.1 Past

The earnings per share for BALY have decreased strongly by -1343.33% in the last year.
The Revenue has grown by 8.57% in the past year. This is quite good.
Measured over the past years, BALY shows a very strong growth in Revenue. The Revenue has been growing by 41.13% on average per year.
EPS 1Y (TTM)-1343.33%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q-445.24%
Revenue 1Y (TTM)8.57%
Revenue growth 3Y87.29%
Revenue growth 5Y41.13%
Revenue growth Q2Q6.06%

3.2 Future

The Earnings Per Share is expected to grow by 23.35% on average over the next years. This is a very strong growth
Based on estimates for the next years, BALY will show a decrease in Revenue. The Revenue will decrease by -4.23% on average per year.
EPS Next Y52.82%
EPS Next 2Y26.92%
EPS Next 3Y23.35%
EPS Next 5YN/A
Revenue Next Year5.18%
Revenue Next 2Y4.5%
Revenue Next 3Y-4.23%
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.

1

4. Valuation

4.1 Price/Earnings Ratio

BALY reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for BALY. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, BALY is valued a bit cheaper than the industry average as 67.16% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 8.85

4.3 Compensation for Growth

A more expensive valuation may be justified as BALY's earnings are expected to grow with 23.35% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y26.92%
EPS Next 3Y23.35%

0

5. Dividend

5.1 Amount

BALY does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

BALLY'S CORP

NYSE:BALY (5/2/2024, 7:04:01 PM)

After market: 13 0 (0%)

13

-0.16 (-1.22%)

Chartmill FA Rating
GICS SectorConsumer Discretionary
GICS IndustryGroupConsumer Services
GICS IndustryHotels, Restaurants & Leisure
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap525.59M
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -2.73%
ROE -29.52%
ROCE
ROIC
ROICexc
ROICexgc
OM 4.27%
PM (TTM) N/A
GM 54.87%
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.36
Health
Industry RankSector Rank
Debt/Equity 5.73
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 0.65
Quick Ratio 0.64
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-1343.33%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y52.82%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)8.57%
Revenue growth 3Y87.29%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y